Indexing
      

Top Links



Open Access Journals

All Science and Engineering articles published in our Open Access journals are freely accessible to read, download and share..

Publish Your Research Papers

Annex Publishers is a hub for scientists and researchers who work hand in hand to bring a much better tomorrow for human race.
  • Annex Publishers

    Annex Publishers, as an Open Access publication model allows the dissemination of research articles to the worldwide community. We offer you the advantage of interaction with the most effective minds from the scientific community. All articles printed under open access will be accessed by anyone.
  • Why Open Access?

    Provides for unrestricted access to journals and publications, along with an ideal platform for thousands of scholarly brains to return together for development of science. Open Access helps accelerate the pace of scientific discovery, encourage innovation, enrich education, and stimulate the economy to enhance the knowledge of the general public.
Submit Manuscript


Recent Articles

Metabolic Syndrome in Indigenous Amerindian Women in Suriname; Less on Waist and More on Weight?

The indigenous Amerindian populations living in the southern interior part of Suriname have to date largely maintained their traditional hunter-gatherer life-style. In this study we compared the prevalence of metabolic syndrome (MeTS) and its component risk factors between indigenous Amerindian women of the interior of Suriname, with indigenous Amerindian women living in the coastal-rural areas who have a more urbanized lifestyle. We focused on women since the Suriname Health study showed that Indigenous women had the second highest MeTS prevalence nationwide.

Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas

This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.